Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
Background. Current guidelines recommend an oral anticoagulant (OAC) monotherapy in patients with nonvalvular atrial fibrillation (NVAF) and stable coronary artery disease (CAD) 1 year postpercutaneous coronary intervention (PCI). It might be possible to shorten the time for de-escalation from a dua...
Saved in:
Main Authors: | Daisuke Fukamachi, Yasuo Okumura, Naoya Matsumoto, Eizo Tachibana, Koji Oiwa, Makoto Ichikawa, Hironori Haruta, Kazumiki Nomoto, Ken Arima, Atsushi Hirayama |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Journal of Interventional Cardiology |
Online Access: | http://dx.doi.org/10.1155/2022/5905022 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model
by: Daisuke Kitano, et al.
Published: (2025-03-01) -
Spontaneous Spinal Epidural Hematoma in a Patient on Apixaban for Nonvalvular Atrial Fibrillation
by: Ahmad El Alayli, et al.
Published: (2020-01-01) -
Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
by: Kenichi Nitta, et al.
Published: (2016-01-01) -
Novel Models for the Prediction of Left Atrial Appendage Thrombus in Patients with Chronic Nonvalvular Atrial Fibrillation
by: Do Van Chien, et al.
Published: (2019-01-01) -
Biomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation
by: Xue Zhou, et al.
Published: (2020-01-01)